| Year |
Citation |
Score |
| 2023 |
Abdulhaleem M, Ruiz J, O'Neill S, Hughes RT, Qasem S, Strowd RE, Furdui C, Watabe K, Miller LD, Debinski W, Tatter S, Metheny-Barlow L, White JJ, Lee J, McTyre ER, et al. Collagen deposition within brain metastases is associated with leptomeningeal failure after
cavity-directed radiosurgery. Neuro-Oncology Advances. 5: vdac186. PMID 36789023 DOI: 10.1093/noajnl/vdac186 |
0.435 |
|
| 2022 |
Lyu Q, Namjoshi SV, McTyre E, Topaloglu U, Barcus R, Chan MD, Cramer CK, Debinski W, Gurcan MN, Lesser GJ, Lin HK, Munden RF, Pasche BC, Sai KKS, Strowd RE, et al. A transformer-based deep-learning approach for classifying brain metastases into primary organ sites using clinical whole-brain MRI images. Patterns (New York, N.Y.). 3: 100613. PMID 36419451 DOI: 10.1016/j.patter.2022.100613 |
0.457 |
|
| 2022 |
Helis CA, Prim SN, Cramer CK, Strowd R, Lesser GJ, White JJ, Tatter SB, Laxton AW, Whitlow C, Lo HW, Debinski W, Ververs JD, Black PJ, Chan MD. Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma. Neuro-Oncology Practice. 9: 390-401. PMID 36134018 DOI: 10.1093/nop/npac032 |
0.437 |
|
| 2020 |
Sharma P, Sonawane P, Herpai D, D'Agostino R, Rossmeisl J, Tatter S, Debinski W. Multireceptor targeting of glioblastoma. Neuro-Oncology Advances. 2: vdaa107. PMID 33150335 DOI: 10.1093/noajnl/vdaa107 |
0.537 |
|
| 2020 |
Renfrow JJ, Soike MH, West JL, Ramkissoon SH, Metheny-Barlow L, Mott RT, Kittel CA, D'Agostino RB, Tatter SB, Laxton AW, Frenkel MB, Hawkins GA, Herpai D, Sanders S, Sarkaria JN, ... ... Debinski W, et al. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Scientific Reports. 10: 15195. PMID 32938997 DOI: 10.1038/S41598-020-72290-2 |
0.553 |
|
| 2020 |
Hassan MS, Pullikuth A, Nelson KC, Flores A, Karpova Y, Baiz D, Zhu S, Sui G, Huang Y, D'Agostino R, Hemal A, von Holzen U, Debinski W, Kulik G. Beta2-adrenoreceptor signaling increases therapy-resistance in prostate cancer by upregulating MCL1. Molecular Cancer Research : McR. PMID 32928910 DOI: 10.1158/1541-7786.Mcr-19-1037 |
0.328 |
|
| 2020 |
Rossmeisl JH, Herpai D, Quigley M, Cecere TE, Robertson JL, D'Agostino RB, Hinckley J, Tatter SB, Dickinson PJ, Debinski W. Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas. Neuro-Oncology. PMID 32812637 DOI: 10.1093/Neuonc/Noaa196 |
0.569 |
|
| 2020 |
Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, et al. Expression of the of the androgen receptor governs radiation resistance in a subset of glioblastomas vulnerable to anti-androgen therapy. Molecular Cancer Therapeutics. PMID 32796101 DOI: 10.1158/1535-7163.Mct-20-0095 |
0.344 |
|
| 2020 |
Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel, Switzerland). 13. PMID 32340173 DOI: 10.3390/Ph13040077 |
0.426 |
|
| 2020 |
Sanders S, Debinski W. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. International Journal of Molecular Sciences. 21. PMID 32316096 DOI: 10.3390/Ijms21082759 |
0.311 |
|
| 2019 |
Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, et al. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Scientific Reports. 9: 14385. PMID 31591443 DOI: 10.1038/S41598-019-50298-7 |
0.318 |
|
| 2019 |
Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Regua AT, Arrigo A, Anguelov M, ... ... Debinski W, et al. TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. Oncogene. PMID 31462709 DOI: 10.1038/S41388-019-0959-3 |
0.349 |
|
| 2019 |
Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Anguelov M, Arrigo A, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Pasche BC, ... Debinski W, et al. Abstract 3689: Tumor-specific gain-of-function tGLI1 transcription factor is a novel mediator of breast cancer stem cells and a novel transcriptional activator of cancer stemness genes Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3689 |
0.3 |
|
| 2019 |
Rimkus TK, Zhu D, Carpenter RL, Paw I, Arrigo A, Sirkisoon S, Doheny D, Aguayo N, Lee J, Jin G, Spooner E, Pasche B, Debinski W, Lo H. Abstract 3481: Roles of tumor suppressor candidate 2 (TUSC2) in glioblastoma progression and gliomagenesis Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3481 |
0.312 |
|
| 2019 |
Sharma P, Herpai D, Rossmeisl J, Tatter S, Debinski W. Exth-54. Multivalent Targeted Proteins For Glioblastoma Treatment Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.385 |
0.509 |
|
| 2019 |
Sanders S, Herpai D, Miller L, Debinski W. TMIC-36. ALDH1A2 AS A NOVEL PUTATIVE MARKER OF MACROPHAGE DIFFERENTIATION IN GBM Neuro-Oncology. 21: vi255-vi255. DOI: 10.1093/Neuonc/Noz175.1070 |
0.323 |
|
| 2018 |
Mao C, Li F, Zhao Y, Debinski W, Ming X. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. Theranostics. 8: 6274-6290. PMID 30613297 DOI: 10.7150/Thno.29580 |
0.409 |
|
| 2018 |
Sharma P, Debinski W. Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences. 19. PMID 30366424 DOI: 10.3390/Ijms19113326 |
0.417 |
|
| 2018 |
Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, ... ... Debinski W, et al. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. PMID 30094640 DOI: 10.1007/S00234-018-2060-Y |
0.503 |
|
| 2018 |
Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE. Hypoxia-inducible factor 2α: a novel target in gliomas. Future Medicinal Chemistry. PMID 30089425 DOI: 10.4155/Fmc-2018-0163 |
0.345 |
|
| 2018 |
Mao C, Zhao Y, Li F, Li Z, Tian S, Debinski W, Ming X. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 30081143 DOI: 10.1016/J.Jconrel.2018.08.005 |
0.37 |
|
| 2018 |
Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, et al. Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Research. PMID 30026327 DOI: 10.1158/0008-5472.Can-18-1102 |
0.366 |
|
| 2018 |
Rimkus TK, Carpenter RL, Sirkisoon SR, Zhu D, Pasche B, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW. Truncated glioma-associated oncogene homolog 1 (tGLI1) mediates mesenchymal glioblastoma via transcriptional activation of CD44. Cancer Research. PMID 29463580 DOI: 10.1158/0008-5472.Can-17-2933 |
0.552 |
|
| 2018 |
Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, et al. Use of non-ionizing electromagnetic fields for the treatment of cancer. Frontiers in Bioscience (Landmark Edition). 23: 284-297. PMID 28930547 DOI: 10.2741/4591 |
0.357 |
|
| 2018 |
Zielinski R, Tworowska I, Skora S, Rusin A, Venugopal R, Jayakumar A, Fokt I, Kang Y, Fleming J, Huang Y, Herpai D, Debinski W, Priebe W. Abstract 1927: Targeting IL-13RA2 in melanoma and pancreatic cancer Cancer Research. 78: 1927-1927. DOI: 10.1158/1538-7445.Am2018-1927 |
0.37 |
|
| 2018 |
Rossmeisl J, Herpai D, Robertson J, Dickinson P, Tatter S, Debinski W. EXTH-43. EFFECTIVE TREATMENT OF CANINE SPONTANEOUS GLIOMAS WITH A CYTOTOXIC COCKTAIL TARGETING IL-13RA2 AND EphA2 RECEPTORS Neuro-Oncology. 20: vi94-vi94. DOI: 10.1093/Neuonc/Noy148.391 |
0.546 |
|
| 2018 |
Sharma P, Herpai D, Rossmeisl J, Tatter S, Debinski W. EXTH-29. MULTI-RECEPTOR TARGETING IN GBM Neuro-Oncology. 20: vi91-vi91. DOI: 10.1093/Neuonc/Noy148.378 |
0.526 |
|
| 2017 |
Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, et al. Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Oncotarget. 8: 73947-73963. PMID 29088759 DOI: 10.18632/Oncotarget.18166 |
0.305 |
|
| 2017 |
Sai KKS, Sattiraju A, Almaguel FG, Xuan A, Rideout S, Krishnaswamy RS, Zhang J, Herpai DM, Debinski W, Mintz A. Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker. Oncotarget. 8: 50997-51007. PMID 28881623 DOI: 10.18632/Oncotarget.16549 |
0.376 |
|
| 2017 |
Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Translational Medicine. 3: 69-79. PMID 28825042 DOI: 10.4103/Ctm.Ctm_12_17 |
0.612 |
|
| 2017 |
Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS. Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophysical Journal. 113: 472-480. PMID 28746857 DOI: 10.1016/J.Bpj.2017.06.014 |
0.348 |
|
| 2017 |
Sattiraju A, Sai KKS, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. PMID 28562337 DOI: 10.18632/Oncotarget.17792 |
0.349 |
|
| 2017 |
Rossmeisl JH, Hall-Manning K, Robertson JL, King JN, Davalos RV, Debinski W, Elankumaran S. Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors. Oncotargets and Therapy. 10: 2077-2085. PMID 28442916 DOI: 10.2147/Ott.S132964 |
0.361 |
|
| 2017 |
McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. American Journal of Clinical Oncology. PMID 28301347 DOI: 10.1097/Coc.0000000000000380 |
0.49 |
|
| 2017 |
Renfrow J, Mott R, Huang Y, Wong T, Lesser GJ, Debinski W, Strowd RE. In situ expression of hypoxia inducible factor 2-alpha in gliomas. Journal of Clinical Oncology. 35: e13534-e13534. DOI: 10.1200/Jco.2017.35.15_Suppl.E13534 |
0.313 |
|
| 2017 |
Sattiraju A, Xuan A, Almaguel F, Herpai D, Debinski W, Mintz A, Sai KKS. Abstract 1831: PET/CT imaging of interleukin-13 receptor alpha-2-targeted peptide to glioblastoma after locoregional delivery Cancer Research. 77: 1831-1831. DOI: 10.1158/1538-7445.Am2017-1831 |
0.35 |
|
| 2017 |
Sonawane P, Herpai D, Ferluga S, Tatter SB, Debinski W. P08.13 A single pharmaceutic agent for molecular resection of Glioblastoma Neuro-Oncology. 19: iii56-iii56. DOI: 10.1093/Neuonc/Nox036.203 |
0.474 |
|
| 2017 |
Rossmeisl JH, Herpai D, Robertson JL, Dickinson PJ, Tatter SB, Debinski W. P08.12 Tolerability and initial efficacy of convection-enhanced delivery of combinatorial IL-13RA2 and EphA2 targeted cytotoxins to dogs with spontaneous intracranial malignant gliomas Neuro-Oncology. 19: iii56-iii56. DOI: 10.1093/Neuonc/Nox036.202 |
0.535 |
|
| 2016 |
Hughes RT, Black PJ, Page BR, Lucas JT, Qasem SA, Watabe K, Ruiz J, Laxton AW, Tatter SB, Debinski W, Chan MD. Local control of brain metastases after stereotactic radiosurgery: the impact of whole brain radiotherapy and treatment paradigm. Journal of Radiosurgery and Sbrt. 4: 89-96. PMID 29296433 |
0.435 |
|
| 2016 |
Stuart CH, Riley KR, Boyacioglu O, Herpai DM, Debinski W, Qasem S, Marini FC, Colyer CL, Gmeiner WH. Selection of a Novel Aptamer Against Vitronectin Using Capillary Electrophoresis and Next Generation Sequencing. Molecular Therapy. Nucleic Acids. 5: e386. PMID 27845768 DOI: 10.1038/Mtna.2016.91 |
0.324 |
|
| 2016 |
Randolph DM, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Clinical Neurology and Neurosurgery. 151: 73-78. PMID 27816029 DOI: 10.1016/J.Clineuro.2016.10.012 |
0.489 |
|
| 2016 |
Soike M, McTyre E, Holmes JA, Paulsson AK, Miller L, Lesser GJ, Strowd RE, Johnson A, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic Predictors of Imaging Response and Survival in Glioblastoma. International Journal of Radiation Oncology, Biology, Physics. 96: E121-E122. PMID 27673833 DOI: 10.1016/J.Ijrobp.2016.06.895 |
0.463 |
|
| 2016 |
Ferluga S, Tomé CM, Herpai DM, D'Agostino R, Debinski W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget. PMID 27494882 DOI: 10.18632/Oncotarget.10978 |
0.422 |
|
| 2016 |
Jimenez H, Wang M, Sharma S, Herpai D, Lesser GJ, Debinski W, Costa F, Barbault A, Blackman C, Pasche B. EXTH-41. THE ANTI-PROLIFERATIVE EFFECTS OF RF EMF AMPLITUDE-MODULATED (AM RF EMF) AT TUMOR SPECIFIC FREQUENCIES ON GLIOBLASTOMA CELLS Neuro-Oncology. 18: vi68-vi68. DOI: 10.1093/Neuonc/Now212.285 |
0.304 |
|
| 2015 |
Rodriguez A, Tatter SB, Debinski W. Neurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment. Pharmaceutics. 7: 175-87. PMID 26247958 DOI: 10.3390/Pharmaceutics7030175 |
0.509 |
|
| 2015 |
Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Journal of Neuro-Oncology. 124: 447-53. PMID 26186902 DOI: 10.1007/S11060-015-1858-2 |
0.486 |
|
| 2015 |
Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, et al. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget. PMID 26087184 DOI: 10.18632/Oncotarget.4153 |
0.536 |
|
| 2015 |
Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW. Mechanisms regulating glioma invasion. Cancer Letters. 362: 1-7. PMID 25796440 DOI: 10.1016/J.Canlet.2015.03.015 |
0.369 |
|
| 2015 |
Carpenter RL, Paw I, Sirkisoon S, Xing F, Gibo D, Watabe K, Debinski W, Lo H. Abstract 4165: The gain-of-function truncated GLI1 (TGLI1) promotes glioblastoma angiogenesis by direct upregulation of VEGF-C and TEM7 expression Cancer Research. 75: 4165-4165. DOI: 10.1158/1538-7445.Am2015-4165 |
0.341 |
|
| 2015 |
Sonawane P, Ferluga S, Herpai D, Debinski W. ATPS-81SINGLE-AGENT TARGETING OF Eph RECEPTORS A2, A3, B2 AND INTERLUKIN-13 RECEPTOR ALPHA 2 IN GLIOBLASTOMA Neuro-Oncology. 17: v36.2-v36. DOI: 10.1093/Neuonc/Nov204.81 |
0.436 |
|
| 2015 |
Herpai D, Ferluga S, Debinski W. ATPS-24MULTI-COMPARTMENTAL TARGETING OF GLIOBLASTOMA THROUGH THE EphA3 RECEPTOR Neuro-Oncology. 17: v23.2-v23. DOI: 10.1093/Neuonc/Nov204.24 |
0.434 |
|
| 2015 |
Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design Journal of Neuro-Oncology. DOI: 10.1007/s11060-015-1858-2 |
0.404 |
|
| 2015 |
Johnson AG, Ruiz J, Hughes R, Brandi RP, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, et al. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases Oncotarget. 6: 18945-18955. |
0.452 |
|
| 2014 |
Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors (Chur, Switzerland). 32: 190-201. PMID 25418012 DOI: 10.3109/08977194.2014.985787 |
0.395 |
|
| 2014 |
Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Journal of Neuro-Oncology. 119: 429-35. PMID 24990827 DOI: 10.1007/S11060-014-1515-1 |
0.516 |
|
| 2014 |
Rossmeisl JH, Garcia PA, Daniel GB, Bourland JD, Debinski W, Dervisis N, Klahn S. Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients. Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association. 55: 115-32. PMID 24219161 DOI: 10.1111/Vru.12118 |
0.334 |
|
| 2014 |
Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. American Journal of Clinical Oncology. 37: 177-81. PMID 23211224 DOI: 10.1097/Coc.0B013E318271Ae03 |
0.495 |
|
| 2014 |
Rodriguez A, Gibo D, Debinski W. ME-18 * INDUCTION OF M2 TYPE MACROPHAGES BY GBM CELLS Neuro-Oncology. 16: v123-v123. DOI: 10.1093/Neuonc/Nou261.17 |
0.347 |
|
| 2014 |
Ferluga S, Gibo D, Debinski W. BI-09 * EphA3 RECEPTOR IS A MOLECULAR TARGET EXPRESSED IN MULTIPLE COMPARTMENTS OF GBM Neuro-Oncology. 16: v25-v25. DOI: 10.1093/Neuonc/Nou239.9 |
0.415 |
|
| 2014 |
Debinski W, Rodriguez A, Gibo D, Tatter SB, Mott R, Lively M, Miller L, Seals DF. FUNCTIONAL PRESENCE OF M2 MACROPHAGE MARKERS IN GBM TUMOR CELLS Neuro-Oncology. 16: iii40-iii41. DOI: 10.1093/Neuonc/Nou208.66 |
0.536 |
|
| 2014 |
Randolph D, Peiffer A, Paulsson A, Hinson W, Laxton A, Tatter S, Debinski W, Chan M. Does Delay of Start of Radiation Affect Clinical Outcomes of Glioblastoma International Journal of Radiation Oncology*Biology*Physics. 90: S295. DOI: 10.1016/J.Ijrobp.2014.05.994 |
0.468 |
|
| 2014 |
Holmes J, Paulsson A, Peiffer A, Miller L, Xu J, Hinson W, Lesser G, Tatter S, Debinski W, Chan M. Genomic Predictors of Infield and Marginal Failure for Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide: A Step Towards Personalized Radiation Fields? International Journal of Radiation Oncology*Biology*Physics. 90: S291-S292. DOI: 10.1016/J.Ijrobp.2014.05.985 |
0.475 |
|
| 2013 |
Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia (New York, N.Y.). 15: 1172-83. PMID 24204196 DOI: 10.1593/Neo.13986 |
0.339 |
|
| 2013 |
Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. Plos One. 8: e77719. PMID 24147065 DOI: 10.1371/Journal.Pone.0077719 |
0.379 |
|
| 2013 |
Nguyen V, Zhu D, Conyers JM, Debinski W, Mintz A. Abstract 2150: Therapeutic efficacy of an optimized quadruply mutated IL13-based bacterial cytotoxin in an orthotopic murine glioma model. Cancer Research. 73: 2150-2150. DOI: 10.1158/1538-7445.Am2013-2150 |
0.442 |
|
| 2013 |
Campian J, Gladstone D, Ambady P, Ye X, King K, Borrello I, Petrik S, Golightly M, Holdhoff M, Grossman S, Bhardwaj R, Chakravadhanula M, Ozols V, Georges J, Carlson E, ... ... Debinski W, et al. IMMUNOTHERAPY/BIOLOGICAL THERAPIES Neuro-Oncology. 15: iii68-iii74. DOI: 10.1093/Neuonc/Not178 |
0.546 |
|
| 2013 |
Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, ... ... Debinski W, ... ... Debinski W, et al. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 15: iii37-iii61. DOI: 10.1093/Neuonc/Not176 |
0.55 |
|
| 2012 |
Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro-Oncology. 14: 1239-53. PMID 22952195 DOI: 10.1093/Neuonc/Nos211 |
0.427 |
|
| 2012 |
Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Molecular and Cellular Biology. 32: 3253-64. PMID 22688511 DOI: 10.1128/Mcb.06791-11 |
0.75 |
|
| 2012 |
Pandya H, Debinski W. Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 26: 235-44. PMID 22671766 DOI: 10.2165/11631600-000000000-00000 |
0.642 |
|
| 2012 |
Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. The Journal of Biological Chemistry. 287: 14012-22. PMID 22362770 DOI: 10.1074/Jbc.M111.311670 |
0.352 |
|
| 2012 |
Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Seminars in Cell & Developmental Biology. 23: 109-15. PMID 22040911 DOI: 10.1016/J.Semcdb.2011.10.019 |
0.749 |
|
| 2012 |
Pandya H, Gibo DM, Garg S, Kridel S, Debinski W. An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro-Oncology. 14: 6-18. PMID 21946118 DOI: 10.1093/Neuonc/Nor141 |
0.622 |
|
| 2012 |
Debinski W. Opinion and Evidence in Cancer American Journal of Cancer. 1: 435-440. DOI: 10.2165/00024669-200201060-00006 |
0.3 |
|
| 2012 |
Ferluga S, Debinski W. Abstract 3860: Glycosylation is indispensable for ephrin A1 activity Cancer Research. 72: 3860-3860. DOI: 10.1158/1538-7445.Am2012-3860 |
0.424 |
|
| 2012 |
Brognaro E, Ghods A, Feinstein D, Glick R, Connolly KJ, Meetze K, Boudrow A, Gyuris J, Han M, Hingtgen S, Figueiredo J, Farrar C, Farrar C, Deubgen M, Martinez-Quintanilla J, ... ... Debinski W, et al. LAB-TUMOR MODELS (IN VIVO/IN VITRO) Neuro-Oncology. 14: vi160-vi164. DOI: 10.1093/Neuonc/Nos241 |
0.301 |
|
| 2012 |
Kijima N, Hosen N, Kagawa N, Hashimoto N, Chiba Y, Kinoshita M, Sugiyama H, Yoshimine T, Kim YZ, Kim KH, Lee EH, Hu B, Sim H, Mohan N, Agudelo-Garcia P, ... ... Debinski W, ... ... Debinski W, et al. LAB-CELL BIOLOGY AND SIGNALING Neuro-Oncology. 14: vi7-vi20. DOI: 10.1093/Neuonc/Nos220 |
0.739 |
|
| 2012 |
Proescholdt MA, Merrill MJ, Stoerr E, Lohmeier A, Brawanski A, Sim H, Hu B, Pineda CA, Yoon S, Viapiano MS, Rajappa P, Cobb WS, Huang Y, Lyden DC, Bromberg J, ... ... Debinski W, et al. LAB-ANGIOGENESIS AND INVASION Neuro-Oncology. 14: vi1-vi6. DOI: 10.1093/Neuonc/Nos219 |
0.317 |
|
| 2012 |
Pandya H, Debinski W. Toward Intracellular Targeted Delivery of Cancer Therapeutics Biodrugs. 26: 235-244. DOI: 10.1007/Bf03261882 |
0.634 |
|
| 2011 |
Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A. IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Translational Oncology. 4: 390-400. PMID 22191003 DOI: 10.1593/Tlo.11175 |
0.422 |
|
| 2011 |
Debinski W, Gibo DM. Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. Cancer Biology & Therapy. 11: 254-62. PMID 21088499 DOI: 10.4161/Cbt.11.2.13953 |
0.355 |
|
| 2011 |
Gonzalez OA, Seals D, Debinski W. Abstract LB-115: EphA2/ephrinA1 system may regulate invadopodia formation of glioblastoma multiforme (GBM) cells Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-115 |
0.318 |
|
| 2011 |
Pandya H, Garg S, Gibo DM, Kridel SJ, Debinski W. Abstract 4141: A heptapeptide specific for Interleukin 13 receptor alpha 2 homes to the receptor-positive human GBM xenografts Cancer Research. 71: 4141-4141. DOI: 10.1158/1538-7445.Am2011-4141 |
0.606 |
|
| 2011 |
Nguyen V, Conyers JM, Zhu D, Hantgan RR, Debinski W, Mintz A. Abstract 3639: In vivo targeting of a Glioblastoma Multiforme restricted biomarker Cancer Research. 71: 3639-3639. DOI: 10.1158/1538-7445.Am2011-3639 |
0.418 |
|
| 2011 |
Baiz D, Yancey D, Choi YA, Baurin V, Karpova Y, Hassan S, Debinski W, Kulik G. Abstract 183: Loss of Bad phosphorylation and Mcl-1 expression is necessary for rapid apoptosisinduced by combination of TGFα-PE and ZSTK474 in prostate cancer cells Cancer Research. 71: 183-183. DOI: 10.1158/1538-7445.Am2011-183 |
0.312 |
|
| 2011 |
Conyers JM, Nguyen V, Murphy T, Beauchamp AS, Hantgan RR, Debinski W, Mintz A. Abstract 1650: Combinatorial targeting of GBM: A means of therapeutically overcoming tumor heterogeneity Cancer Research. 71: 1650-1650. DOI: 10.1158/1538-7445.Am2011-1650 |
0.768 |
|
| 2011 |
Beauchamp A, Wykosky J, Mintz A, Gibo D, Debinski W. Abstract 1218: Investigation of the mechanism and form of ephrinA1 released from cancer cells Cancer Research. 71: 1218-1218. DOI: 10.1158/1538-7445.Am2011-1218 |
0.759 |
|
| 2011 |
Nguyen V, Conyers JM, Zhu D, Hantgan R, Larson SM, Debinski W, Mintz A. Abstract B112: Personalizing anti-IL13R 2 therapy with real-time immunoPET visualization of biomarker expression. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B112 |
0.437 |
|
| 2010 |
Debinski W, Tatter SB. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation. Current Opinion in Molecular Therapeutics. 12: 647-53. PMID 21154156 |
0.499 |
|
| 2010 |
Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proceedings of the National Academy of Sciences of the United States of America. 107: 20021-6. PMID 21030678 DOI: 10.1073/Pnas.1008261107 |
0.414 |
|
| 2010 |
Pandya H, Gibo DM, Debinski W. Molecular targeting of intracellular compartments specifically in cancer cells. Genes & Cancer. 1: 421-33. PMID 20740056 DOI: 10.1177/1947601910375274 |
0.63 |
|
| 2010 |
Nguyen V, Hollingsworth C, Debinski W, Mintz A. Abstract 5525: Targeting the IL13Rα2 tumor-restricted biomarker with a novel ligand delivery system Cancer Research. 70: 5525-5525. DOI: 10.1158/1538-7445.Am10-5525 |
0.351 |
|
| 2010 |
Pandya H, Gibo D, Debinski W. Abstract 5519: Development of ‘multiple-specificity’ vectors for targeted delivery to intracellular organelles of the glioblastoma multiforme tumor cells Cancer Research. 70: 5519-5519. DOI: 10.1158/1538-7445.Am10-5519 |
0.633 |
|
| 2010 |
Tome CML, Palma E, Wykoski J, Debinski W. Abstract 5465: Functional and structural characterization of the high-affinity EphA2-binding site of ephrinA1 Cancer Research. 70: 5465-5465. DOI: 10.1158/1538-7445.Am10-5465 |
0.413 |
|
| 2010 |
Calipari ES, Tallant EA, Lesser G, Debinski W, Gallagher PE. Abstract 3575: Angiotensin-(1-7) and temozolomide provide combinatorial inhibition of glioblastoma cell growth Cancer Research. 70: 3575-3575. DOI: 10.1158/1538-7445.Am10-3575 |
0.395 |
|
| 2009 |
Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Review of Neurotherapeutics. 9: 1519-27. PMID 19831841 DOI: 10.1586/Ern.09.99 |
0.555 |
|
| 2009 |
Liu TF, Cai J, Gibo DM, Debinski W. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 160-8. PMID 19118043 DOI: 10.1158/1078-0432.Ccr-08-2151 |
0.398 |
|
| 2008 |
Chen J, Zhuang G, Frieden L, Debinski W. Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Research. 68: 10031-3. PMID 19074866 DOI: 10.1158/0008-5472.Can-08-3010 |
0.345 |
|
| 2008 |
Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Molecular Cancer Research : McR. 6: 1795-806. PMID 19074825 DOI: 10.1158/1541-7786.Mcr-08-0244 |
0.409 |
|
| 2008 |
Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski W. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biotherapy & Radiopharmaceuticals. 23: 581-9. PMID 18976118 DOI: 10.1089/Cbr.2008.0462 |
0.36 |
|
| 2008 |
Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor Oncogene. 27: 7260-7273. PMID 18794797 DOI: 10.1038/Onc.2008.328 |
0.382 |
|
| 2008 |
Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 199-208. PMID 18172271 DOI: 10.1158/1078-0432.Ccr-07-1990 |
0.338 |
|
| 2008 |
Debinski W. Molecular targeting with recombinant cytotoxins for the treatment of brain tumors Drug Development Research. 69: 407-414. DOI: 10.1002/Ddr.20272 |
0.393 |
|
| 2007 |
Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Molecular Cancer Therapeutics. 6: 3208-18. PMID 18089715 DOI: 10.1158/1535-7163.Mct-07-0200 |
0.426 |
|
| 2006 |
Debinski W. Naturally occurring, unmodified bacterial toxin for the treatment of glioblastoma multiforme? Cancer Biology & Therapy. 5: 1569-70. PMID 17204857 DOI: 10.4161/Cbt.5.11.3656 |
0.324 |
|
| 2005 |
Couture D, Wykosky J, Gibo DM, Debinski W. 866 EphA2 Receptor Represents a New Marker and Therapeutic Target in Pediatric Malignancies. Neurosurgery. 57: 418-419. PMID 28184793 DOI: 10.1093/Neurosurgery/57.2.418C |
0.329 |
|
| 2005 |
Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Molecular Cancer Research : McR. 3: 541-51. PMID 16254188 DOI: 10.1158/1541-7786.Mcr-05-0056 |
0.41 |
|
| 2005 |
Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Molecular Cancer Research : McR. 3: 237-49. PMID 15831677 DOI: 10.1158/1541-7786.Mcr-05-0004 |
0.377 |
|
| 2004 |
Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia (New York, N.Y.). 6: 15-22. PMID 15068667 DOI: 10.1016/S1476-5586(04)80049-6 |
0.32 |
|
| 2003 |
Mintz A, Gibo DM, Madhankumar AB, Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. Journal of Neuro-Oncology. 64: 117-23. PMID 12952292 DOI: 10.1007/Bf02700026 |
0.323 |
|
| 2003 |
Debinski W, Gibo D, Mintz A. Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Annals of the New York Academy of Sciences. 983: 232-42. PMID 12724228 DOI: 10.1111/J.1749-6632.2003.Tb05978.X |
0.402 |
|
| 2002 |
Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proceedings of the National Academy of Sciences of the United States of America. 99: 15124-9. PMID 12417744 DOI: 10.1073/Pnas.232588699 |
0.349 |
|
| 2002 |
Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Investigation. 20: 801-9. PMID 12197239 DOI: 10.1081/Cnv-120003545 |
0.367 |
|
| 2002 |
Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (New York, N.Y.). 4: 388-99. PMID 12192597 DOI: 10.1038/Sj.Neo.7900234 |
0.332 |
|
| 2002 |
Madhankumar AB, Mintz A, Debinski W. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. The Journal of Biological Chemistry. 277: 43194-205. PMID 12189139 DOI: 10.1074/Jbc.M205047200 |
0.321 |
|
| 2001 |
Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, Gibo DM. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. Molecular Medicine (Cambridge, Mass.). 7: 598-608. PMID 11778649 DOI: 10.1007/Bf03401866 |
0.32 |
|
| 2001 |
Nash KT, Thompson JP, Debinski W. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins Critical Reviews in Oncology/Hematology. 39: 87-98. PMID 11418305 DOI: 10.1016/S1040-8428(01)00124-X |
0.319 |
|
| 2000 |
Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. Journal of Neuro-Oncology. 48: 103-11. PMID 11083073 DOI: 10.1023/A:1006446426611 |
0.384 |
|
| 2000 |
Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen Molecular Medicine (Cambridge, Mass.). 6: 440-449. PMID 10952023 DOI: 10.1007/Bf03401786 |
0.344 |
|
| 2000 |
Mintz A, Debinski W. Cancer genetics/epigenetics and the X chromosome: Possible new links for malignant glioma pathogenesis and immune-based therapies Critical Reviews in Oncogenesis. 11: 77-95. PMID 10795628 DOI: 10.1615/Critrevoncog.V11.I1.40 |
0.372 |
|
| 1999 |
Debinski W. Recombinant cytotoxins specific for cancer cells Annals of the New York Academy of Sciences. 886: 297-299. PMID 10667244 DOI: 10.1111/J.1749-6632.1999.Tb09441.X |
0.327 |
|
| 1999 |
Thompson JP, Debinski W. Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors Journal of Biological Chemistry. 274: 29944-29950. PMID 10514477 DOI: 10.1074/Jbc.274.42.29944 |
0.345 |
|
| 1999 |
Debinski W, Gibo DM, Slagle B, Powers SK, Gillespie GY. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme International Journal of Oncology. 15: 481-486. PMID 10427128 DOI: 10.3892/Ijo.15.3.481 |
0.377 |
|
| 1999 |
Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas Clinical Cancer Research. 5: 985-990. PMID 10353730 |
0.301 |
|
| 1998 |
Debinski W, Gibo DM, Obiri NI, Kealiher A, Puri RK. Novel anti-brain tumor cytotoxins specific for cancer cells Nature Biotechnology. 16: 449-453. PMID 9592393 DOI: 10.1038/Nbt0598-449 |
0.407 |
|
| 1998 |
Debinski W, Gibo DM, Puri RK. Novel way to increase targeting specificity to a human gliblastoma- associated receptor for interleukin 13 International Journal of Cancer. 76: 547-551. PMID 9590132 DOI: 10.1002/(Sici)1097-0215(19980518)76:4<547::Aid-Ijc17>3.0.Co;2-4 |
0.376 |
|
| 1997 |
Maini A, Hillman G, Haas GP, Wang CY, Montecillo E, Hamzavi F, Edson Pontes J, Leland P, Pastan I, Debinski W, Puri RK. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of pseudomonas exotoxin Journal of Urology. 158: 948-953. PMID 9258124 DOI: 10.1016/S0022-5347(01)64369-6 |
0.371 |
|
| 1995 |
Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1253-8. PMID 9815919 |
0.304 |
|
| 1994 |
Debinski W, Puri RK, Pastan I. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin International Journal of Cancer. 58: 744-748. PMID 8077061 DOI: 10.1002/Ijc.2910580520 |
0.313 |
|
| Show low-probability matches. |